These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 8645080)

  • 21. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
    Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
    Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synchronous occurrence of anaplastic, follicular and papillary carcinomas with follicular adenoma in thyroid gland.
    Bhargav PR; Gayathri KB
    Indian J Pathol Microbiol; 2011; 54(2):414-5; author reply 415. PubMed ID: 21623114
    [No Abstract]   [Full Text] [Related]  

  • 23. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
    Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
    Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. miR-126-3p Inhibits Thyroid Cancer Cell Growth and Metastasis, and Is Associated with Aggressive Thyroid Cancer.
    Xiong Y; Kotian S; Zeiger MA; Zhang L; Kebebew E
    PLoS One; 2015; 10(8):e0130496. PubMed ID: 26244545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
    Bartolome A; Boskovic S; Paunovic I; Bozic V; Cvejic D
    APMIS; 2016 Apr; 124(4):271-7. PubMed ID: 26750533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNA methylation signatures identify biologically distinct thyroid cancer subtypes.
    Rodríguez-Rodero S; Fernández AF; Fernández-Morera JL; Castro-Santos P; Bayon GF; Ferrero C; Urdinguio RG; Gonzalez-Marquez R; Suarez C; Fernández-Vega I; Fresno Forcelledo MF; Martínez-Camblor P; Mancikova V; Castelblanco E; Perez M; Marrón PI; Mendiola M; Hardisson D; Santisteban P; Riesco-Eizaguirre G; Matías-Guiu X; Carnero A; Robledo M; Delgado-Álvarez E; Menéndez-Torre E; Fraga MF
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2811-21. PubMed ID: 23666970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRAF mutation detection in indeterminate thyroid cytology specimens: underlying cytologic, molecular, and pathologic characteristics of papillary thyroid carcinoma.
    Ohori NP; Singhal R; Nikiforova MN; Yip L; Schoedel KE; Coyne C; McCoy KL; LeBeau SO; Hodak SP; Carty SE; Nikiforov YE
    Cancer Cytopathol; 2013 Apr; 121(4):197-205. PubMed ID: 22887810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular genotyping of the non-invasive encapsulated follicular variant of papillary thyroid carcinoma.
    Kim TH; Lee M; Kwon AY; Choe JH; Kim JH; Kim JS; Hahn SY; Shin JH; Chung MK; Son YI; Ki CS; Yim HS; Kim YL; Chung JH; Kim SW; Oh YL
    Histopathology; 2018 Mar; 72(4):648-661. PubMed ID: 28940583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blood group antigen expression in malignant tumors of the thyroid: a parallel between medullary and nonmedullary carcinomas.
    Larena A; Vierbuchen M; Fischer R
    Langenbecks Arch Chir; 1995; 380(5):269-72. PubMed ID: 7500798
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Down-regulation of transcription elogation factor A (SII) like 4 (TCEAL4) in anaplastic thyroid cancer.
    Akaishi J; Onda M; Okamoto J; Miyamoto S; Nagahama M; Ito K; Yoshida A; Shimizu K
    BMC Cancer; 2006 Nov; 6():260. PubMed ID: 17076909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Familial nonmedullary thyroid carcinoma.
    Malchoff CD; Malchoff DM
    Cancer Control; 2006 Apr; 13(2):106-10. PubMed ID: 16735984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Familial nonmedullary thyroid cancer. An emerging entity that warrants aggressive treatment.
    Grossman RF; Tu SH; Duh QY; Siperstein AE; Novosolov F; Clark OH
    Arch Surg; 1995 Aug; 130(8):892-7; discussion 898-9. PubMed ID: 7632152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Familial nommedullary thyroid cancer].
    Santos RB; Melo TG; Assumpção LV
    Arq Bras Endocrinol Metabol; 2007 Jul; 51(5):769-73. PubMed ID: 17891240
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Correlations between cytology and histology in thyroid pathology. Case 2. Possible malignant lesion (insular carcinoma/poorly differentiated follicular carcinoma)].
    Cochand-Priollet B
    Ann Pathol; 2009 Apr; 29(2):91-4. PubMed ID: 19364580
    [No Abstract]   [Full Text] [Related]  

  • 35. Gene Fusions in Thyroid Cancer.
    Yakushina VD; Lerner LV; Lavrov AV
    Thyroid; 2018 Feb; 28(2):158-167. PubMed ID: 29281951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thyroid tumors with follicular architecture.
    Turk AT; Wenig BM
    Ann Diagn Pathol; 2019 Feb; 38():51-58. PubMed ID: 30419427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Histological variants (subtypes) of differentiated thyroid carcinoma].
    Abduluakhab M; Mikhaĭlov I; Gavrilov M
    Khirurgiia (Sofiia); 1997; 50(3):31-4. PubMed ID: 9739840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunohistochemical study of glypican 3 in thyroid cancer.
    Yamanaka K; Ito Y; Okuyama N; Noda K; Matsumoto H; Yoshida H; Miyauchi A; Capurro M; Filmus J; Miyoshi E
    Oncology; 2007; 73(5-6):389-94. PubMed ID: 18511877
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Family with nonmedullary thyroid neoplasms.
    Kobayashi K; Tanaka Y; Ishiguro S; Mori T; Mitani Y; Shigemasa C
    J Surg Oncol; 1995 Apr; 58(4):274-7. PubMed ID: 7723373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can the microRNA signature distinguish between thyroid tumors of uncertain malignant potential and other well-differentiated tumors of the thyroid gland?
    Lassalle S; Hofman V; Ilie M; Bonnetaud C; Puisségur MP; Brest P; Loubatier C; Guevara N; Bordone O; Cardinaud B; Lebrigand K; Rios G; Santini J; Franc B; Mari B; Al Ghuzlan A; Vielh P; Barbry P; Hofman P
    Endocr Relat Cancer; 2011 Oct; 18(5):579-94. PubMed ID: 21778212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.